Cellular cardiomyoplasty: Development of a technique to culture human myoblasts for clinical transplantation

被引:5
|
作者
Rendal Vázquez M.E. [1 ,4 ]
Rodriguez Cabarcos M. [1 ]
Díaz Román T. [2 ]
Juffé Stein A. [3 ]
Doménech García N. [2 ]
Adrio Nazar B. [3 ]
Sánchez Dopico M.J. [2 ]
Andión Núñez C. [1 ]
Blanco García F.J. [2 ]
机构
[1] Cryobiology Unit, Complejo Hospitalario Juan Canalejo, La Coruña
[2] Unit of Investigation, Complejo Hospitalario Juan Canalejo, La Coruña
[3] Department of Cardiac Surgery, Complejo Hospitalario Juan Canalejo, La Coruña
[4] Unit of Cryobiology, Hospital Teresa Herrera, 15006 La Coruña, Carretera del Pasaje s/n
关键词
CD56; Cellular cardiomyoplasty; Cytometry; Desmin; Immunohistochemistry; Myoblast;
D O I
10.1007/s10561-004-7990-4
中图分类号
学科分类号
摘要
Some recent studies have demonstrated that epicardial injection of autologous myoblasts, obtained from satellite cells of skeletal muscle, in association to coronary artery bypass graft surgery (CABG) in patients with decreased left ventricular function secondary to ischaemic disease could be of some utility to get a better recovery of ventricular function due to the ability of these cells to grow and generate new muscle fibers over the previous fibrotic scar. The aims are the setting up of a process for the collection of the cellular cardiomyoplasty in samples of multiorganic donations and to carry out this technique in the same surgical moment as the revascularisation is performed in two patients. For this purpose we obtained muscle through biopsy of 15 human multiorgan donors and of two patients. Separation of fatty tissue, minced, and further digestion with collagenase type I (1.5 mgr/ml/2 gr by weight) and trypsin 1×. Filtration of the cellular suspension, centrifugation and sowing of this suspension in culture medium, with 20% of human serum. Culture for three weeks until obtainment of between 200-300 million cells. Inmunohistochemistry and flow cytometry for the identification of the myoblasts was carried out. The results were obtained through flow cytometry, using CD56 as an indicator of the presence of myoblasts, between 70 and 80% of these types of cells were obtained after three weeks of culture. By inmunohistochemistry analyses, different markers were analyzed: desmin and myogenin. The results indicated the presence of a great number of positive cells with these markers, possibly myoblasts. Skeletal myoblast implant was not associated with adverse effects. The culture of autologous myoblasts is a rapid and simple technique where after three weeks of culture a great number of cells for implantation are obtained. In patients with old myocardial infarction, treatment with skeletal myoblast in conjunction with coronary artery bypass is safe and feasible. and it is easy to obtain myoblasts from muscle tissue for transplant into patients. © Springer 2005.
引用
收藏
页码:117 / 124
页数:7
相关论文
共 50 条
  • [1] Percutaneous transendocardial delivery of skeletal myoblasts for cellular cardiomyoplasty: Phase I multicenter clinical trial
    Smits, PC
    Serruys, PW
    Nienaber, CA
    Ince, H
    Carlino, M
    Colombo, A
    CIRCULATION, 2003, 108 (17) : 623 - 623
  • [2] Cellular cardiomyoplasty: Clinical application
    Chachques, JC
    Acar, C
    Herreros, J
    Trainini, JC
    Prosper, F
    D'Attellis, N
    Fabiani, JN
    Carpentier, AF
    ANNALS OF THORACIC SURGERY, 2004, 77 (03): : 1121 - 1130
  • [3] Cellular cardiomyoplasty using genetically modified skeletal myoblasts for cardiac repair
    Ye, L
    Haider, KH
    Jiang, SJ
    Tan, RS
    Ge, RW
    Law, PK
    Aziz, S
    Sim, EKW
    HYPERTENSION, 2005, 46 (04) : 888 - 888
  • [4] Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts
    Hutcheson, KA
    Atkins, BZ
    Hueman, MT
    Hopkins, MB
    Glower, DD
    Taylor, DA
    CELL TRANSPLANTATION, 2000, 9 (03) : 359 - 368
  • [5] Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure
    Doris A Taylor
    Trials, 2 (5)
  • [6] Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts
    Retuerto, Mauricio A.
    Beckmann, James T.
    Carbray, JoAnn
    Patejunas, Gerald
    Sarateanu, Sorin
    Kane, Bonnie J.
    Smulevitz, Beverly
    McPherson, David D.
    Rosengart, Todd K.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 133 (02): : 478 - U41
  • [7] Clinical cellular cardiomyoplasty: Technical considerations
    Zhang, FM
    Yang, ZJ
    Chen, YJ
    Qin, JW
    Zhu, TB
    Xu, D
    Xu, ZQ
    Xu, QB
    Qian, Y
    Ma, WZ
    Chen, LZ
    Gao, X
    Li, CF
    Ha, TZ
    Kao, RL
    JOURNAL OF CARDIAC SURGERY, 2003, 18 (03) : 268 - 273
  • [8] Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure
    Taylor, DA
    CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2001, 2 (05): : 208 - A210
  • [9] Preliminary experience of catheter based transendocardial delivery of autologous skeletal myoblasts for cellular cardiomyoplasty
    Smits, PC
    Maat, L
    Lee, RCH
    Poldermans, D
    van Geuns, RJ
    Cummins, PA
    van der Giessen, WJ
    Serruys, PW
    EUROPEAN HEART JOURNAL, 2002, 23 : 506 - 506
  • [10] Cellular cardiomyoplasty - cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?
    Reffelmann, T
    Kloner, RA
    CARDIOVASCULAR RESEARCH, 2003, 58 (02) : 358 - 368